{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-059106","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.734047+00:00","generated_at":"2026-06-02T06:31:09.490008+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioXcel Q1 net loss narrows to $26.8M on IGALMI revenue growth of 182% YoY","bullets":["IGALMI net revenue $582K (Q1 2024), up 182% YoY and 55% sequentially.","Net loss of $26.8M vs $52.8M in Q1 2023; operating cash used $17.7M.","Cash $74.1M at March 31, 2024, including $25M from March direct offering.","Advanced two Phase 3 trials for BXCL501: TRANQUILITY In-Care (60 mcg) for Alzheimer's agitation and SERENITY At-Home (120 mcg) for bipolar/schizophrenia; FDA protocol submitted.","Two new patents granted for BXCL501 (Japan and U.S.) extending protection to 2039/2043."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-059106","json":"https://secwatch.observer/filing/0001104659-24-059106.json","markdown":"https://secwatch.observer/filing/0001104659-24-059106.md","text":"https://secwatch.observer/filing/0001104659-24-059106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924059106/0001104659-24-059106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924059106/tm249625d5_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:31:09.490008+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"272a2eb81a74fd12ed532e233d4784e8e36a6ff9","claim":"BioXcel Therapeutics, Inc. reported first quarter of 2024 results: revenue $582,000, net income $26.8 million.","evidence_excerpt":"of BXCL701 and KEYTRUDA® (pembrolizumab) in metastatic pancreatic ductal adenocarcinoma (PDAC). First Quarter 2024 Financial Results Net Revenue: Net revenue from IGALMI was $582,000 for the first quarter of 2024, compared to $206,000 for the same period in 2023, representing a 182% increase. Sequential quarterly revenue increased 55% in Q1 2024 from the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924059106/0001104659-24-059106-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Revenue","value":"$582,000"},{"label":"Net income","value":"$26.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}